Next Article in Journal
Echinacea purpurea (L.) Moench: Chemical Characterization and Bioactivity of Its Extracts and Fractions
Previous Article in Journal
Diterpenoids from Plectranthus spp. as Potential Chemotherapeutic Agents via Apoptosis
Open AccessCommunication

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

1
Departments of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA
3
Departments of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(6), 124; https://doi.org/10.3390/ph13060124
Received: 12 May 2020 / Revised: 26 May 2020 / Accepted: 11 June 2020 / Published: 16 June 2020
(This article belongs to the Section Pharmacology)
Outcomes of acute lymphoblastic leukemia (ALL) in older adults treated with chemotherapy are poor. The CD19/CD3 bispecific T-cell engager (BiTE) antibody blinatumomab is approved for refractory, relapsed or minimal/measurable residual disease (MRD)-positive B-cell ALL, but there is little experience in the upfront setting, including in older patients. We retrospectively analyzed outcomes of blinatumomab monotherapy in five newly diagnosed Philadelphia chromosome-negative B-cell ALL patients over 70 years. Three had cytokine release syndrome, treated with dexamethasone and/or tocilizumab, and four patients had neurotoxicity, treated with dexamethasone, without blinatumomab interruption. All five achieved complete remission (CR) after cycle one, three with undetectable MRD. All five were alive at 8 to 15 months. Three remained in MRD-negative CR. Two relapsed after cycle 3, one with extramedullary disease. In our small cohort of patients over 70 years, blinatumomab was safe initial therapy and produced a high response rate. View Full-Text
Keywords: blinatumomab; acute lymphoblastic leukemia (ALL); elderly blinatumomab; acute lymphoblastic leukemia (ALL); elderly
Show Figures

Graphical abstract

MDPI and ACS Style

Niyongere, S.; Sanchez-Petitto, G.; Masur, J.; Baer, M.R.; Duong, V.H.; Emadi, A. Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Pharmaceuticals 2020, 13, 124.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop